Alcon, Novartis' former eye disease unit, continues dealmaking spree with $770M Aerie acquisition

After picking up two drugs from a Bob Langer spinout in a deal earlier this year, Alcon is staying busy.

The former Novartis subsidiary focused …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Al­con, No­var­tis' for­mer eye dis­ease unit, con­tin­ues deal­mak­ing spree with $770M Aerie ac­qui­si­tion